GuideNephrology
Membranous nephropathy prognosis (Toronto model and KDIGO risk stratification)
Reading sheet on estimating the risk of kidney failure in primary membranous nephropathy from persistent proteinuria, kidney function and current markers.
Updated 3 November 2026
When to use it
Adults with primary membranous nephropathy (usually anti-PLA2R positive) after an observation period on supportive therapy, to decide whether to start immunosuppression.
Toronto model
Derived from the Toronto Glomerulonephritis Registry (184 patients) to predict chronic renal insufficiency (creatinine clearance ≤ 60 ml/min/1.73 m² sustained ≥ 12 months). Prognostic variables were:
• The highest proteinuria sustained over a 6-month period.
• Initial creatinine clearance.
• The slope (rate of change) of clearance over those 6 months.
It was validated in cohorts from Italy (101) and Finland (78) with accuracy ≥ 85%. The original equations are not reproduced here because their units and scales could not be verified.
Keep reading in the app
- KDIGO 2021 risk stratification
- Treatment implications
- Limitations
Practical tip
Proteinuria at biopsy alone predicts poorly; what matters is the highest proteinuria sustained over 6 months, together with initial clearance and its slope.
2 more practical tips in the app.
Reference
- Pei Y, Cattran D, Greenwood C. Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992;42(4):960-966.
- Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 1997;51(3):901-907.
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
